Amy Marie Nielsen, MOTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3924 S Orchard Dr, North Salt Lake, UT 84054 Phone: 801-381-5806 |
Marcel Dransfield, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 665 Cutler Dr, North Salt Lake, UT 84054 Phone: 801-936-0318 |
Heather S Prisbrey Johnson, MOT, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 585 Lofty Ln, North Salt Lake, UT 84054 Phone: 801-541-0612 |
Mrs. Hang Chien Li Hammond, MA,OTR/L,CLT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 730 Leeds Ct, North Salt Lake, UT 84054 Phone: 201-606-5950 |
Living Labs Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 585 Lofty Ln, North Salt Lake, UT 84054 Phone: 801-541-0612 |
News Archive
Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).
Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This application expands the investigational utility of Epic Sciences' no cell left behind™ platform to characterize circulating tumor cell (CTC) genomic alterations.
Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, biomarker development and aging research, is pleased to announce the presentation of its Director of Drug Discovery, Dr. Ivan Ozerov, at the 24th Clinical Applications for Age Management Medicine Conference, April 27, 2018, organized by Age Management Medicine Group.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.
Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.
› Verified 2 days ago